Results 21 to 30 of about 5,996,360 (285)

Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]

, 2011
Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Eble, Johannes Andreas, Navdaev, Alexey
core   +2 more sources

Increased survival with enzalutamide in prostate cancer after chemotherapy.

New England Journal of Medicine, 2012
BACKGROUND Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. de Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. D. de Bono   +19 more
semanticscholar   +1 more source

The molecular basis for ethnic variation and histological subtype differences in prostate cancer. [PDF]

, 2013
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China.
Goldstein, Andrew S, Huang, Jiaoti, Zong, Yang   +2 more
core   +1 more source

Hedgehog Signalling in Androgen Independent Prostate Cancer [PDF]

, 2008
Objectives: Androgen-deprivation therapy effectively shrinks hormone-naïve prostate cancer, both in the prostate and at sites of distant metastasis.
Bisson, Isabelle, Ktori, Elena, McFaul, Siobhan, Oliver, R. Tim D, Price, Anna M., Prowse, David M., Purkis, Patricia E., Shaw, Greg   +7 more
core   +1 more source

A cross-sectional comparison of quality of life between physically active and underactive older men with prostate cancer [PDF]

, 2016
Men with prostate cancer experience many side effects and symptoms that may be improved by a physically active lifestyle. It was hypothesized that older men with prostate cancer who were physically active would report significantly higher levels of ...
Boisen, Samara, Gray, Marion, Keogh, Justin W., Krägeloh, Chris, MacLeod, Rod D., Masters, Jonathan, Osborne, Sue, Ryan, Clare, Shepherd, Daniel   +8 more
core   +1 more source

Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics [PDF]

, 2012
Background: Lipids have critical functions in cellular energy storage, structure and signaling. Many individual lipid molecules have been associated with the evolution of prostate cancer; however, none of them has been approved to be used as a ...
AA Elgamal, B Brügger, BR Pflug, CG Rogers, Charles Pound, Christina Lynn Addison, D Pchejetski, EF Petricoin, F Bravi, F Teichert, FL Crowe, G Balogh, G Draisma, G Liebisch, H He, HK Min, IM Thompson, IM Thompson, J Ding, J Graessler, J Graessler, J Kurhanewicz, Jeffrey Henegar, Jinghe Mao, JR Graff, Junmei Ai, K Athenstaedt, K Ekroos, K Simons, KA Landers, KH Pietiläinen, KR Keshari, L Zhuang, M Kolak, M Lankinen, M Ollero, Mary R. Roth, MG Swanson, ML Ramírez, O Quehenberger, R Bartz, R Etzioni, R Görke, R Welti, RJ Hamilton, RS Kirby, Ruth Welti, S Devaiah, Steven A. Bigler, TC Gibbs, VD de Mello, VL Freeman, X Han, X Han, X Zhou, Xinchun Zhou, Y Xie, Y Zeng, Youping Deng   +58 more
core   +7 more sources

WNT signalling in prostate cancer [PDF]

, 2017
Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-
A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine   +166 more
core   +2 more sources

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

The Lancet, 2017
BACKGROUND Men with high serum prostate specific antigen usually undergo transrectal ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects including bleeding, pain, and infection. Multi-parametric magnetic resonance imaging (
H. Ahmed, A. El-Shater Bosaily, L. Brown, R. Gabe, R. Kaplan, M. Parmar, Y. Collaco-Moraes, Katie Ward, R. Hindley, A. Freeman, A. Kirkham, R. Oldroyd, C. Parker, M. Emberton   +13 more
semanticscholar   +1 more source

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources